What is claimed is:

1. ~~A~~ Use of ~~method for treating a lymphoma in a subject, comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of an anti-cancer therapy, wherein the~~ anti-cancer agent ~~is~~ represented by Formula (I):



(I),

or a pharmaceutically acceptable salt thereof~~;~~ in the manufacture of medicament for the treatment of lymphoma in a subject in combination with at least one anti-cancer therapy selected from the group consisting of ~~and wherein the anti-cancer therapy comprises a combination of~~ rituximab, cyclophosphamide, doxorubicin or a pharmaceutically acceptable salt thereof, vincristine or a pharmaceutically acceptable salt thereof, and prednisolone.

2. The use ~~method~~ of claim 1, wherein the lymphoma is a Hodgkin lymphoma.

3. The ~~method~~ use of claim 1, wherein the lymphoma is a non-Hodgkin lymphoma

4. The use ~~method~~ of claim 1 or 3, wherein the lymphoma is a B-cell lymphoma.

5. The use ~~method~~ of any one of ~~Claims~~ claims 1, 3, and 4, wherein the lymphoma is selected from follicular lymphoma, DLBCL, MCL, Burkitt, and lymphoplasmacytic lymphoma.

6. The ~~method~~ use of any one of ~~Claims~~ claims 1 and 3 to 5, wherein the lymphoma is selected from DLBCL, MCL, and Burkitt lymphoma.

7. The ~~method~~ use of any one of ~~Claims~~ claims 1 and 3 to 6, wherein the lymphoma is selected from DLBCL and MCL.

8. The ~~method~~ use of any one of ~~Claims~~ claims 1 and 3 to 6, wherein the lymphoma is DLBCL.

9. The ~~method~~ use of claim 1 or 3, wherein the lymphoma is a T-cell lymphoma.

10. The ~~method~~ use of any one of claims 1, 3, and 9, wherein the lymphoma is a cutaneous T-cell lymphoma.

11. The ~~method~~ use of any one of claims 1, 3, 9, and 10, wherein the lymphoma is selected from mycosis fungoide, PTCL, AITL, ALCL, EATL, and hepatosplenic gamma/delta T-cell lymphoma.

12. The ~~method~~ use of any one of claims 1 to 11, wherein the anti-cancer agent and the anti-cancer therapy are administered simultaneously in the same or different formulations.

13. The ~~method~~ use of any one of claims 1 to 12, wherein the anti-cancer agent and the anti-cancer therapy are administered sequentially.

14. The ~~method~~ use of any one of claims 1 to 13, wherein the anti-cancer agent is the tris(hydroxymethyl)aminomethane salt of the compound of Formula (I).

15. The ~~method~~ use of any one of claims 1 to 14, wherein the anti-cancer agent is the sodium salt of the compound of Formula (I).

16. The ~~method~~ use of any one of claims 1 to 15, wherein the doxorubicin is doxorubicin hydrochloride.

17. The ~~method~~ use of any one of claims 1 to 16, wherein the vincristine is vincristine sulfate.